AIFA has updated the methods of use of monoclonal antibodies against COVID-19 in relation to the new evidence from the literature that has recently become available. In particular, a positive opinion was given to the use of the sotrovimab antibody which demonstrated a favorable benefit / risk ratio also against the main circulating variants of SARS-CoV-2. Also for the approval of [...]
read more
As part of the epidemiological emergency from Coronavirus, the Italian Medicines Agency (AIFA), through a specific call, has promoted the funding of some studies to acquire new evidence on the efficacy of monoclonal antibodies in the treatment of patients affected by COVID- 19 in an early stage of illness, not hospitalized and whether or not they have risk factors that may aggravate [...]
read more
“The advantage of this medicine is that it gives you immediate antibodies - explains Catherine Houlihan, a virologist at University College London Hospital (Uclh). We could tell trial participants who have been exposed: 'yes, you can have the vaccine'. But we cannot assure them that it will protect them from the disease, because it is too late: current vaccines do not confer immunity [...]
read more